GT
SYRE icon

Glenmede Trust’s Spyre Therapeutics SYRE Stock Holding History

Glenmede Trust’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$885K Buy
+9,966
New +$727K ﹤0.01% 809

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Glenmede Trust's SYRE Position: Q2 2026 in Review

Glenmede Trust opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 9,966 shares worth $885K. The stake represents ﹤0.01% of the portfolio and ranks #809 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Glenmede Trust held 9,966 shares of Spyre Therapeutics worth $885K as of Q2 2026.
  • Spyre Therapeutics was a new Glenmede Trust position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #809 holding.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.